Joanne L Jones

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9562518/publications.pdf

Version: 2024-02-01

58 papers	4,273 citations	147786 31 h-index	149686 56 g-index
66 all docs	66 docs citations	66 times ranked	4745 citing authors

#	Article	IF	Citations
1	The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 2006, 253, 98-108.	3.6	469
2	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
3	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology, 2005, 35, 3332-3342.	2.9	279
4	Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science, 2022, 376, eabl5197.	12.6	265
5	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Journal of Clinical Investigation, 2009, 119, 2052-61.	8.2	257
6	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 208-215.	1.9	208
7	B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. Journal of Clinical Immunology, 2010, 30, 99-105.	3.8	207
8	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20200-20205.	7.1	185
9	Distinct microbial and immune niches of the human colon. Nature Immunology, 2020, 21, 343-353.	14.5	175
10	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain, 2013, 136, 2888-2903.	7.6	174
11	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 298-304.	1.9	171
12	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain, 2010, 133, 2232-2247.	7.6	152
13	Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology, 2013, 81, 872-876.	1.1	120
14	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
15	Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Review of Neurotherapeutics, 2012, 12, 335-341.	2.8	86
16	A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. Journal of Immunology, 2010, 185, 763-768.	0.8	65
17	Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Medicine, 2020, 12, 55.	8.2	61
18	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 87, 473-488.	4.1	58

#	Article	IF	Citations
19	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3010-3018.	3.6	57
20	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology, 2014, 82, 2158-2164.	1.1	52
21	Mode of action and clinical studies with alemtuzumab. Experimental Neurology, 2014, 262, 37-43.	4.1	51
22	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight, 2017, 2, .	5.0	46
23	2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. European Thyroid Journal, 2019, 8, 173-185.	2.4	44
24	Immunological considerations and challenges for regenerative cellular therapies. Communications Biology, 2021, 4, 798.	4.4	44
25	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, The, 2021, 20, 709-720.	10.2	44
26	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 795-798.	1.9	42
27	New treatment strategies in multiple sclerosis. Experimental Neurology, 2010, 225, 34-39.	4.1	39
28	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Journal of Neurology, 2016, 263, 25-29.	3.6	39
29	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain, 2018, 141, 786-796.	7.6	39
30	Extracellular Lactate: A Novel Measure of T Cell Proliferation. Journal of Immunology, 2018, 200, 1220-1226.	0.8	39
31	Campath-1H Treatment of Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 27-31.	1.4	34
32	'Radiologically compatible CLIPPERS' may conceal a number of pathologies. Brain, 2011, 134, e187-e187.	7.6	33
33	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. Frontiers in Neurology, 2018, 9, 870.	2.4	33
34	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology, 2018, 90, 849-851.	1.1	32
35	Neuroanatomical substrates of generalized brain dysfunction in COVID-19. Intensive Care Medicine, 2021, 47, 116-118.	8.2	31
36	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1779-1782.	3.0	25

#	Article	IF	Citations
37	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.8	24
38	Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73. Communications Biology, 2021, 4, 1186.	4.4	19
39	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight, 2019, 4, .	5.0	16
40	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
41	Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23 Na-MRI. Journal of the Neurological Sciences, 2018, 387, 111-114.	0.6	10
42	Transcript specific regulation of expression influences susceptibility to multiple sclerosis. European Journal of Human Genetics, 2020, 28, 826-834.	2.8	10
43	The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro. Frontiers in Immunology, 2021, 12, 712241.	4.8	9
44	Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. EJNMMI Research, 2020, 10, 82.	2.5	9
45	Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis. PLoS ONE, 2016, 11, e0158327.	2.5	9
46	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. Multiple Sclerosis Journal, 2020, 26, 1093-1101.	3.0	6
47	A case of anaphylaxis to alemtuzumab. Journal of Neurology, 2019, 266, 780-781.	3.6	6
48	Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	5
49	The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinsonâ€™s disease. Neuronal Signaling, 2021, 5, NS20200083.	3.2	3
50	Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab. Clinical Immunology, 2010, 135, S103.	3.2	2
51	FIRST USE OF ALEMTUZUMAB IN BALO CONCENTRIC SCLEROSIS: A CASE REPORT. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.81-e2.	1.9	2
52	Meeting abstracts from the 64th British Thyroid Association Annual Meeting. Thyroid Research, 2017, 10, .	1.5	2
53	Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2019, 266, 1539-1540.	3.6	2
54	Progressive multifocal leucoencephalopathy with BehÃ§etâ€™s disease: an insight into pathophysiology. Rheumatology, 2017, 56, kew404.	1.9	1

#	Article	IF	Citations
55	The yin and yang of intracellular reactive oxygen species following T-cell activation. Brain, 2021, 144, 2909-2911.	7.6	1
56	LONG-TERM SAFETY OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: PREGNANCY AND INFECTION DATA FROM A COHORT OF PATIENTS ON OPEN LABEL STUDIES IN CAMBRIDGE. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.15-e4.	1.9	0
57	Targeting CD52 for the Treatment of Multiple Sclerosis. , 2013, , 385-399.		0
58	Graves' disease with fluctuating thyroid status and hypothyroidism with positive anti-TSH receptor antibody levels - distinctive autoimmune side-effects following alemtuzumab therapy for multiple sclerosis. Endocrine Abstracts, 0, , .	0.0	0